How Precisely Can Prostate Cancer Be Managed?.
- Author:
Liyan ZHUANG
1
;
Matthew T JOHNSON
Author Information
- Publication Type:Review
- Keywords: Prostatic Neoplasms; Precision Medicine; Biomarkers; Receptors, Androgen
- MeSH: Biomarkers; Biopsy; Disease Management; Drug Therapy; Humans; Male; Mass Screening; Neoplasm Grading; Neoplasm Metastasis; Precision Medicine; Prostate*; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms*; Receptors, Androgen; Recurrence
- From:International Neurourology Journal 2016;20(Suppl 2):S120-S130
- CountryRepublic of Korea
- Language:English
- Abstract: Progress has been made in applying genetic information to disease management in the postgenomic era, and precision medicine is emerging in prostate cancer management. The prostate health index, the 4-kallikrein (4K) score, and the PCA3, TMPRSS2-ERG, and Prostarix tests have potential for refining prostate cancer screening in conjunction with traditional prostate-specific antigen testing. The Confirm MDx and PCA3 tests have shown promise in identifying men who need be rebiopsied after a primary negative biopsy. Oncotype DX, Prolaris, the biopsy-based Decipher prostate cancer test, and ProMark may improve predictive risk stratification in addition to the traditional Gleason score and tumor stage. Decipher and Prolaris may predict biochemical recurrence and metastasis after radical prostatectomy and possibly help identify patients who need adjuvant therapy. Androgen receptor splice variant 7 appears effective in guiding the selection of second hormonal manipulation with abiraterone or enzalutamide versus chemotherapy when treating metastatic castration-resistant prostate cancer.
